


1. A method for the treatment or prophylaxis, amelioration, defense against, and/or prevention of menopausal syndrome, osteoporosis; premenstrual syndrome; male impotence; Reynaud's Syndrome; Reynaud's Phenomenon; Buerger's Disease; coronary artery spasm; migraine headaches; hypertension, benign prostatic hypertrophy; breast cancer; uterine cancer; ovarian cancer; testicular cancer; large bowel cancer, endometrial cancer; prostatic cancer; leukemia; arteriosclerosis; Alzheimer's disease; inflammatory diseases; rheumatic diseases; acne; baldness; psoriasis and/or diseases associated with oxidant stress comprising administering to a subject a therapeutically effective amount of at least one compound of the formula I:




wherein

Z is H,


R₁ is H, or R_ACO where R_A is C₁₋₁₀ alkyl or an amino acid,

R₂ is H, OH, or OR_B where R_B is an amino acid or COR_A where R_A is C₁₋₁₀ alkyl or an amino acid,


W is H, A is H or OH, and B is selected from




W is H, and A and B taken together form a six membered ring selected from




W, A and B taken with the groups with which they are associated comprise



W and A taken together with the groups with which they are associated comprise



and B is



wherein

R_3 is H, COR_A where R_A is C_{1-10} alkyl or an amino acid, CO_2R_C

where R_C is C_{1-10} alkyl, or

COR_B where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_4 is H, COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid, CO_2R_C where R_C is C_{1-10}

alkyl, COR_E where R_E is H, C_{1-10} alkyl or an amino acid, COOH , COR_C where R_C

is C_{1-10} alkyl, or CONHR_E , where R_E is H, C_{1-10} alkyl or an amino acid,


R_5 is H, CO_2R_C where R_C is C_{1-10} alkyl, or COR_COR_E where R_C is C_{1-10} alkyl and R_E is H,

C_{1-10} alkyl or an amino acid, and with the proviso that where the two R_5 groups are attached to the same group they are identical or different,

R_6 is H or hydroxy C_{1-10} alkyl,

X is O, N or S, and

Y is




where R_7 is H, or C_{1-10} alkyl

with the proviso that compounds of the formula I where


R_1 , W and Z are H

R_2 is H or OH

A and B taken together are a six membered ring



wherein Y is




and R_7 is H or CH_3 ,

are excluded, and


with the proviso that where the method is a method for the treatment or prophylaxis of menopausal syndrome or premenstrual syndrome compounds of the formula I where

R_1 , W and Z are H, and R_2 is H or OH,


A and B taken together are a six membered ring



or A is OH and B is



where Y is




R_7 is H are excluded, and


with the proviso that where the method is a method for treatment of a form of cancer or rheumatoid arthritis compounds of the formula I where:

R_1 and W are H, Z is H or OCH_3 and R_2 is H or OH, and

A and B taken together are a six membered ring of the formula










Y is













R_4 is CO_2H or $CO_2CH_2CH_3$, and R_7 is H are excluded.


2. A method according to claim 1 wherein said at least one compound of the formula I is:












or,



wherein

R_8 is COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid,

R_9 is CO_2R_C or COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid,

R_{10} is COR_C or COR_COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid,

R_{11} is H or OH,

R_{12} is H, COOH, CO_2R_C where R_C is C_{1-10} alkyl, or $CONHR_E$ where R_E is H, C_{1-10} alkyl or an amino acid,

R_{13} is OH, OR_B where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid, or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{14} is H, or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{15} is COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{16} is H, COR_B or CO_2R_C where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid and R_C is C_{1-10} alkyl,

R_{17} is H or hydroxy C_{1-10} alkyl,

R_{18} is H or C_{1-10} alkyl,

and "—" represents either a single bond or double bond.


3. A method according to claim 2, wherein said method is a method for the treatment of menopausal syndrome, hypertension, arteriosclerosis, male impotence, or premenstrual syndrome, further wherein at least one compound of the formulae 1, 3, 8, 10, 11, 13 and 14 is administered to a subject in need thereof, together with a pharmaceutically acceptable carrier or excipient.

4. A method according to claim 2, wherein said method is a method for the treatment of breast, ovarian, testicular, uterine, large bowel, leukemia, endometrial, or prostatic cancer wherein at least one compound of the formulae 1, 8, 10, 11, 13 and 14

is administered to a subject in need thereof, together with a pharmaceutically acceptable carrier or excipient.

5. A method according to claim 2, wherein said method is a method for a disease associated with oxidant stress selected from the group consisting of cancer, myocardial infarction, stroke, arthritis and cataracts comprising administering to a subject in need thereof at least one compound of the formulae 1, 3, 8, 10, 13 and 14 together with a pharmaceutically acceptable carrier and/or excipient.

6. A composition for the treatment, amelioration, defense against, prophylaxis and/or prevention of menopausal syndrome; osteoporosis; premenstrual syndrome; male impotence; Reynaud's Syndrome; Reynaud's Phenomenon; Buerger's Disease; coronary artery spasm; migraine headaches; osteoporosis, hypertension, benign prostatic hypertrophy, breast cancer, uterine cancer; ovarian cancer, testicular cancer; large bowel cancer; endometrial cancer; prostatic cancer; leukemia; arteriosclerosis; inflammatory diseases; rheumatic diseases; acne; baldness; psoriasis and/or diseases associated with oxidant stress, comprising at least one acceptable carrier and/or excipient, and at least one compound of the formula I:




wherein

Z is H,


R₁ is H, or R_ACO where R_A is C₁₋₁₀ alkyl or an amino acid,

R₂ is H, OH, or OR_B where R_B is an amino acid or COR_A where R_A is C₁₋₁₀ alkyl or an amino acid,


W is H, A is H or OH, and B is selected from




W is H, and A and B taken together form a six membered ring selected from




W, A and B taken with the groups with which they are associated comprise



W and A taken together with the groups with which they are associated comprise



and B is



wherein

R_3 is H, COR_A where R_A is C_{1-10} alkyl or an amino acid, CO_2R_C where R_C is C_{1-10} alkyl, or

COR_B where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_4 is H, COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid, CO_2R_C where R_C is C_{1-10} alkyl, COR_E where R_E is H, C_{1-10} alkyl or an amino acid, COOH, COR_C where R_C is C_{1-10} alkyl, or $CONHR_E$, where R_E is H, C_{1-10} alkyl or an amino acid,


R_5 is H, CO_2R_C where R_C is C_{1-10} alkyl, or

COR_COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid, and with the proviso that where the two R_5 groups are attached to the same group they are identical or different,

R_6 is H or hydroxy C_{1-10} alkyl,

X is O, N or S, and

Y is




where R_7 is H or C_{1-10} alkyl

with the proviso that compounds of the formula I where


R_1 , W and Z are H

R_2 is H or OH

A and B taken together are a six membered ring



wherein Y is




and R_7 is H or CH_3 ,

are excluded, and


with the proviso that where the composition is for treatment or prophylaxis of menopausal syndrome or premenstrual syndrome, then compounds of the formula I where

R_1 , W and Z are H, and R_2 is H or OH,


A and B taken together are a six membered ring



or A is OH and B is



where Y is




R₇ is H, are excluded, and


with the proviso that where the composition is for treatment of a form of cancer or rheumatoid arthritis, then compounds of the formula I where

R₁ and W are H, Z is H or OCH₃ and R₂ is H or OH, and

A and B taken together are a six membered ring of the formula












Y is












R₄ is CO₂H or CO₂CH₂CH₃, and R₇ is H are excluded.

7. A composition according to claim 6, wherein said at least one compound of formula I is:










or,



wherein

R_8 is COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid,

R_9 is CO_2R_C or COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid,

R₁₀ is COR_C or COR_COR_E where R_C is C₁₋₁₀ alkyl and R_E is H, C₁₋₁₀ alkyl or an amino acid,

R₁₁ is H or OH,

R₁₂ is H, COOH, CO₂R_C where R_C is C₁₋₁₀ alkyl, or CONHR_E where R_E is H, C₁₋₁₀ alkyl or an amino acid,

R₁₃ is OH, OR_B where R_B is an amino acid or COR_A where R_A

is C₁₋₁₀ alkyl or an amino acid, or COR_A where R_A

is C₁₋₁₀ alkyl or an amino acid,

R₁₄ is H, or COR_A where R_A is C₁₋₁₀ alkyl or an amino acid,

R₁₅ is COR_A where R_A is C₁₋₁₀ alkyl or an amino acid,

R₁₆ is H, COR_B or CO₂R_C where R_B is an amino acid or COR_A where R_A

is C₁₋₁₀ alkyl or an amino acid and R_C is C₁₋₁₀ alkyl,

R₁₇ is H or hydroxy C₁₋₁₀ alkyl,


R₁₈ is H or C₁₋₁₀ alkyl,

and "—" represents either a single bond or a double bond.

10. A composition according to claim 6, wherein said at least one acceptable carrier and/or excipient is at least one pharmaceutically acceptable carrier and/or excipient.

11. A composition according to claim 7 wherein said at least one acceptable carrier and/or excipient is at least one pharmaceutically acceptable carrier and/or excipient.

13. A composition according to claim 6, wherein said at least one acceptable carrier and/or excipient is at least one physiologically and/or cosmetically acceptable carrier and/or excipient.
14. A composition according to claim 13, further comprising vitamin E.
15. A composition according to claim 7, further comprising vitamin E, and wherein said at least one acceptable carrier and/or excipient is at least one physiologically and/or cosmetically acceptable carrier and/or excipient.
16. A composition according to claim 13 in the form of a skin cream or gel.
17. A composition according to claim 13 in the form of a solid dosage unit.
19. A composition according to claim 6, in the form of a food stuff or drink.
20. A composition according to claim 7, in the form of a food stuff or drink.
21. A microorganism which produces at least one compound of the formula I:




wherein

Z is H,


R₁ is H, or R_ACO where R_A is C₁₋₁₀ alkyl or an amino acid,

R₂ is H, OH, or OR_B where R_B is an amino acid or COR_A where R_A is C₁₋₁₀ alkyl or an amino acid,


W is H, A is H or OH, and B is selected from




W is H, and A and B taken together form a six membered ring selected from




W, A and B taken with the groups with which they are associated comprise



W and A taken together with the groups with which they are associated comprise



and B is



wherein

R_3 is H, COR_A where R_A is C_{1-10} alkyl or an amino acid, CO_2R_C where R_C is C_{1-10} alkyl,

or

COR_B where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_4 is H, COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid, CO_2R_C where R_C is C_{1-10}

alkyl, COR_E where R_E is H, C_{1-10} alkyl or an amino acid, COOH, COR_C where R_C

is C_{1-10} alkyl, or $CONHR_E$, where R_E is H, C_{1-10} alkyl or an amino acid,

R_5 is H, CO_2R_C where R_C is C_{1-10} alkyl, or

COR_COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid, and


with the proviso that where the two R_5 groups are attached to the same group

they are identical or different,

R_6 is H or hydroxy C_{1-10} alkyl,

X is O, N or S, and

Y is




where R_7 is H or C_{1-10} alkyl

with the proviso that said at least one compound of the formula I where


R_1 , W and Z are H

R_2 is H or OH

A and B taken together are a six membered ring



wherein Y is




and R_7 is H or CH_3 ,

is excluded, and


with the proviso that where the microorganism produces a compound for treatment or prophylaxis of menopausal syndrome or premenstrual syndrome, then said at least one compound of the formula I where

R_1 , W and Z are H, and R_2 is H or OH,


A and B taken together are a six membered ring



or A is OH and B is



where Y is




R_7 is H is excluded, and


with the proviso that where the microorganism produces a compound for treatment of a form of cancer or rheumatoid arthritis, then said at least one compound of the formula I where

R_1 and W are H, Z is H or OCH_3 and R_2 is H or OH, and

A and B taken together are a six membered ring of the formula












Y is












R_4 is CO_2H or $\text{CO}_2\text{CH}_2\text{CH}_3$, and R_7 is H is excluded.

22. A microorganism according to claim 21 wherein said at least one compound of the formula I is:










or



wherein

R_8 is COR_D where R_D is H, OH, C_{1-10} alkyl or an amino acid,

R_9 is CO_2R_C or COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid,

R_{10} is COR_C or COR_COR_E where R_C is C_{1-10} alkyl and R_E is H, C_{1-10} alkyl or an amino acid,

R_{11} is H or OH,

R_{12} is H, COOH, CO_2R_C where R_C is C_{1-10} alkyl, or $CONHR_E$ where R_E is H, C_{1-10} alkyl or an amino acid,

R_{13} is OH, OR_B where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid, or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{14} is H, or COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{15} is COR_A where R_A is C_{1-10} alkyl or an amino acid,

R_{16} is H, COR_B or CO_2R_C where R_B is an amino acid or COR_A where R_A is C_{1-10} alkyl or an amino acid and R_C is C_{1-10} alkyl,

R_{17} is H or hydroxy C_{1-10} alkyl,

R_{18} is H or C_{1-10} alkyl,

and "—" represents either a single bond or a double bond.

23. A microbial culture or a food stuff comprising at least one microbial strain and at least one microorganism as defined in claim 21.

24. A microbial culture or a food stuff comprising at least one microbial strain further and at least one microorganism as defined in claim 22.

25. A method according to claim 1, wherein said menopausal syndrome is hot flushes, anxiety and depression, mood swings, night sweats, headaches, and urinary incontinence or a combination thereof; wherein said premenstrual syndrome is fluid retention and cyclical mastalgia, dysmenorrhoea, or a combination thereof; wherein said inflammatory diseases are inflammatory bowel disease, ulcerative colitis, Crohns disease, or a combination thereof; wherein said rheumatic disease is rheumatoid arthritis; wherein said baldness is male pattern baldness; and wherein said psoriasis and/or diseases associated with oxidant stress are cancer, myocardial infarction, stroke, arthritis, sunlight induced skin damage, cataracts, or a combination thereof.

26. A method according to claim 1, wherein said X is O.